This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Brown & Crouppen Files Suit Over Infant Death And Illness Linked To Contaminated Formula

Stocks in this article: MJN

St. Louis-based law firm Brown & Crouppen has filed suit against Mead Johnson Nutrition Company (NYSE: MJN), alleging that contaminated Enfamil powdered baby formula was responsible for the death of one infant from meningitis and serious illness in two others.

The lawsuit, Shelby Schrack, et al. v. Mead Johnson Nutrition Company and Mead Johnson & Company, Cause no. 12-L-549, was filed October 16, 2012, in St. Clair County (Illinois) Circuit Court.

According to the lawsuit, 10-day-old Avery Cornett died on Dec. 18, 2011, of meningitis caused by the bacterium Chronobacter sakazakii. Cornett had been fed Enfamil Premium Newborn powdered formula from batch ZP1K7G.

Porsche Rapacz, born Nov. 23, 2011, was fed Enfamil Premium Newborn powdered formula from batch ZP1K7G after her discharge from the hospital on Nov. 25, 2011. She was rehospitalized and treated for meningitis after becoming lethargic and feverish 29 days after her birth.

Nadilynn Mohler, born on Oct. 28, 2011, was fed Enfamil Premium Newborn from batch ZP1GNS and Enfamil Gentlease from batch ZP1HZP after her discharge from the hospital. On Nov. 29, 2011, her parents called the pediatrician because Nadilynn had a fever. A cerebrospinal fluid culture revealed C. sakazakii, and Nadilynn was hospitalized and treated for meningitis.

Babies younger than 29 days do not have mature immune systems, and foods contaminated with certain bacteria can cause serious injury or death. The suit asserts that powdered formula may contain such bacteria as C. sakazakii, which can cause meningitis. The suit also alleges that:

  • Since the beginning of this century, environmental sampling from Mead Johnson’s facilities has revealed harmful bacteria in raw ingredients, premix product and finished products
  • After being alerted in 2001, the U.S. Food and Drug Administration tested newborn food at manufacturing facilities, including those of the defendant, and reported in March 2004 that 23 percent of samples contained harmful bacteria
  • In 2002, J. Roberto Moran, M.D., then a vice president and medical director for Mead Johnson, warned a limited number of healthcare professionals but not consumers: “No infant formula powders made today are commercially sterile…. Therefore we recommend that liquid formulas should be used in hospital settings. We strongly recommend that powdered infant formulas not be used in neonates or immunocompromised patients in hospital settings.”
  • Mead Johnson has refused to publicize or educate caregivers on the critical importance of safe preparation practices such as heating water to at least 150 degrees Fahrenheit
  • Every case of newborn bacterial meningitis documented by the Centers for Disease Control and Prevention has been associated with powdered newborn food except one, and the newborn in that case may have been fed its twin’s food because of a crib card switch that resulted in misidentification.

The suit seeks significant damages for negligence, failure to warn, strict liability, breach of implied warranty of merchantability, express warranty and fraud.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs